drugset / Trial / NCT00002237

A Study of Peldesine (BCX-34) in HIV-Infected Patients

NCT00002237 ↗

Phase 1 Completed BioCryst Pharmaceuticals
Treatment

Summary

The purpose of this study is to determine the highest amount of peldesine that is safe. This study will also see if this amount of peldesine is effective in lowering HIV levels in the blood.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Peldesine Small molecule — Oral